BridgeBio Pharma (BBIO) investor relations material

Key accomplishments and financial outlook

• Achieved a successful launch of Attruby, reaching a $440 million revenue run rate and over 20% share in the treatment-naive ATTR-CM market.

• Reported two positive phase 3 data sets, with Encaleret and BBP-418 showing curative potential in rare diseases.

• Pipeline peak sales potential estimated at $6 billion de-risked and $10 billion including upcoming programs like infegratinib.

• Expansion plans include new phase 3 trials in chronic HP and further data readouts in hypochondroplasia and other rare diseases.

• Maintains a strong financial position with $650 million in cash, flat spending, and increasing revenues, supporting global ambitions.

Attruby market position and differentiation

• Attruby is positioned as the only near-complete stabilizer for ATTR-CM, with rapid onset of effect and strong outcomes in mortality and hospitalization.

• Demonstrated a 50% reduction in cardiovascular hospitalization and 42% reduction in mortality at 30 months.

• Additional data show benefits in subpopulations, including variant and AFib patients, and superiority in serum TTR levels.

• Ongoing real-world evidence and switching studies aim to further differentiate Attruby from competitors and generics.

Encaleret and BBP-418 opportunities

• Encaleret targets a $1 billion+ market in ADH1, with efficacy shown in all patient variants and normalization of calcium levels.

• Phase 2 and 3 data support expansion into chronic HP, with 80% normalization rates and a favorable oral safety profile.

• BBP-418 demonstrated unprecedented functional improvements in limb-girdle muscular dystrophy, with a billion-dollar opportunity and potential for population expansion.